BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38669518)

  • 1. The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer.
    Amansyah F; Prihantono P; Hamid F; Syamsu SA; Pieter J; Faruk M
    Breast Dis; 2024; 43(1):71-78. PubMed ID: 38669518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
    JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
    Press DJ; Miller ME; Liederbach E; Yao K; Huo D
    Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
    Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up.
    Yang SX; Polley EC
    Breast Cancer Res Treat; 2019 Jun; 175(2):287-295. PubMed ID: 30746635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
    Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
    J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
    Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
    Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer.
    Umar SM; Kashyap A; Kahol S; Mathur SR; Gogia A; Deo SVS; Prasad CP
    Exp Cell Res; 2020 Nov; 396(1):112282. PubMed ID: 32919954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of age in different molecular subtypes of breast cancer.
    Liedtke C; Rody A; Gluz O; Baumann K; Beyer D; Kohls EB; Lausen K; Hanker L; Holtrich U; Becker S; Karn T
    Breast Cancer Res Treat; 2015 Aug; 152(3):667-73. PubMed ID: 26195120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
    Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
    Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.
    Zarotti C; Papassotiropoulos B; Elfgen C; Dedes K; Vorburger D; Pestalozzi B; Trojan A; Varga Z
    Sci Rep; 2022 Jan; 12(1):91. PubMed ID: 34997055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.